Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Nintedanib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients with Advanced Colorectal Cancer Refractory to Standard Treatment

Clinical Colorectal Cancer

Volumn 15, Issue 1, 2016, Pages 91-94.e1

  Van Cutsem, Eric ^a   Yoshino, Takayuki ^b   Hocke, Julia ^c   Oum'Hamed, Zohra ^c   Studeny, Matus ^d   Tabernero, Josep ^e  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Angiogenesis; Colorectal; FGF; PDGF; TKI; VEGF

Indexed keywords

NINTEDANIB; PLACEBO; REGORAFENIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE;

ADVANCED CANCER; ARTICLE; BEST SUPPORTIVE CARE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; COLORECTAL CANCER; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; OVERALL SURVIVAL; PATIENT CARE; PHARMACOGENOMICS; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STUDY DESIGN; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; INTENTION TO TREAT ANALYSIS; KAPLAN MEIER METHOD; PATHOLOGY; STATISTICAL MODEL; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; HUMANS; INDOLES; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84960105565     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2015.09.005     Document Type: Article

References (15)

1. E. Van Cutsem, A. Cervantes, B. Nordlinger, and D. Arnold Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 25 2014 iii1 iii9
2. C.E. DeSantis, C.C. Lin, A.B. Mariotto, and et al. Cancer treatment and survivorship statistics, 2014 CA Cancer J Clin 64 2014 252 271
3. J. Capdevila, A. Carrato, J. Tabernero, and E. Grande What could nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer? Crit Rev Oncol Hematol 92 2014 83 106
4. A. Grothey, E. Van Cutsem, A. Sobrero, and et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial Lancet 381 2013 303 312
5. F. Loupakis, C. Cremolini, A. Fioravanti, and et al. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer Br J Cancer 104 2011 1262 1269
6. National Comprehensive Cancer Network. NCCN guidelines: colon cancer, version 2. 2015. Available at: http://www.nccn.org/professionals/physician-gls/pdf/colon.pdf. Accessed: March 10, 2015.
7. J. Tabernero, T. Yoshino, A.L. Cohn, and et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study Lancet Oncol 16 2015 499 508
8. U.S. Food and Drug Administration. FDA approves ramucirumab in combination with FOLFIRI for the treatment of patients with metastatic colorectal cancer after first-line therapy. Available at: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm444496.htm. Accessed: June 3, 2015.
9. S.M. Wilhelm, J. Dumas, L. Adnane, and et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity Int J Cancer 129 2011 245 255
10. ® summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/002573/WC500149164.pdf. Accessed: May 26, 2015.
11. K. Mross, M. Buchert, A. Frost, and et al. Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis BMC Cancer 14 2014 510
12. F. Hilberg, G.J. Roth, M. Krssak, and et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy Cancer Res 68 2008 4774 4782
13. P.L. McCormack Nintedanib: first global approval Drugs 75 2015 129 139
14. G.J. Roth, R. Binder, F. Colbatzky, and et al. Nintedanib: from discovery to the clinic J Med Chem 58 2015 1053 1063
15. E. Van Cutsem, H. Prenen, C. Guillen-Ponce, and et al. A phase l/lI, open-label, randomised study of BIBF 1120 plus mFOLFOX6 compared to bevacizumab plus mFOLFOX6 in patients with metastatic colorectal cancer Eur J Cancer 47 suppl 2 2011 8 9 (abstract)